The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Circadin melatonin | RAD Neurim Pharmaceuticals EEC SARL | Sleep Initiation and Maintenance Disorders | 🇪🇺 EU 2007-06-29 | Order → |
| Siklos hydroxycarbamide | Theravia | Anemia, Sickle Cell | 🇪🇺 EU 2007-06-29 | Order → |
| Pergoveris follitropin alfa;lutropin alfa | Merck Europe B.V. | Infertility, Female | 🇪🇺 EU 2007-06-25 | Order → |
| Invega paliperidone | Janssen-Cilag International NV | Schizophrenia; Psychotic Disorders | 🇪🇺 EU 2007-06-24 | Order → |
| Soliris eculizumab OrphanAccelerated assessment | Alexion Europe SAS | Hemoglobinuria, Paroxysmal | 🇪🇺 EU 2007-06-20 | Order → |
| Revlimid lenalidomide Additional monitoring | Bristol-Myers Squibb Pharma EEIG | Multiple Myeloma; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes | 🇪🇺 EU 2007-06-14 | Order → |
| Optaflu influenza vaccine (surface antigen, inactivated, prepared in cell cultures) | Seqirus GmbH | Influenza, Human; Immunization | 🇪🇺 EU 2007-06-01 | Order → |
| Altargo retapamulin | Glaxo Group Ltd | Impetigo; Staphylococcal Skin Infections | 🇪🇺 EU 2007-05-24 | Order → |
| Orencia abatacept | Bristol-Myers Squibb Pharma EEIG | Arthritis, Psoriatic; Arthritis, Juvenile Rheumatoid; Arthritis, Rheumatoid | 🇪🇺 EU 2007-05-21 | Order → |
| Focetria influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted) | Novartis Vaccines and Diagnostics S.r.l. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2007-05-02 | Order → |
| Sebivo telbivudine | Novartis Europharm Limited | Hepatitis B, Chronic | 🇪🇺 EU 2007-04-24 | Order → |
| Advagraf tacrolimus | Astellas Pharma Europe BV | Graft Rejection | 🇪🇺 EU 2007-04-23 | Order → |
| Docetaxel Zentiva (previously Docetaxel Winthrop) docetaxel | Zentiva k.s. | Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU 2007-04-20 | Order → |
| Toviaz fesoterodine | Pfizer Europe MA EEIG | Urinary Bladder, Overactive | 🇪🇺 EU 2007-04-20 | Order → |
| Daronrix pandemic influenza vaccine (whole virion, inactivated, adjuvanted) Exceptional circumstances | GlaxoSmithKline Biologicals S.A. | Influenza, Human; Immunization; Disease Outbreaks | 🇪🇺 EU 2007-03-21 | Order → |
| Xelevia sitagliptin | Merck Sharp & Dohme B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2007-03-21 | Order → |
| Januvia sitagliptin | Merck Sharp and Dohme B.V | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2007-03-20 | Order → |
| Cystadane betaine anhydrous | Recordati Rare Diseases | Homocystinuria | 🇪🇺 EU 2007-02-14 | Order → |
| Prezista darunavir | Janssen-Cilag International NV | HIV Infections | 🇪🇺 EU 2007-02-11 | Order → |
| Lucentis ranibizumab | Novartis Europharm Limited | Wet Macular Degeneration; Macular Edema; Diabetes Complications; Myopia, Degenerative; Choroidal Neovascularization | 🇪🇺 EU 2007-01-22 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.